A double-blind, multicenter, randomized, placebo-controlled study of safety and efficacy of trospium chloride 60 mg modified release capsules versus placebo, once daily, for 12 weeks followed by a 9-month, open label treatment phase in patients with overactive bladder
Phase of Trial: Phase III
Latest Information Update: 01 Apr 2011
At a glance
- Drugs Trospium chloride (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Endo Pharmaceuticals Solutions
- 01 Mar 2008 Results have been published.
- 05 Apr 2006 New trial record.